FDA Oncology posted on X:
“FDA article outlines the decision-making process and rationale behind removal or narrowing of certain indications for PARP inhibitors in treatment of advanced ovarian cancer – via Journal of Clinical Oncology.”
Title: Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer
Authors: Mirat Shah, Ting-Yu Chen, Gwynn Ison, Mallorie H. Fiero, Hui Zhang, Xin Gao, Marc Neilson, Kirsten B. Goldberg, Abhilasha Nair, Tiffany K. Ricks, William F. Pierce, Nicole Gormley, Marc R. Theoret, Shenghui Tang, Richard Pazdur, Paul G. Kluetz, Laleh Amiri-Kordestani
Read The Full Article at ASCO Publications.
More posts featuring Ovarian Cancer.